The signal, the score, and the play — in one place.

Purpose-built for Life Sciences commercial leaders. Not a dashboard. The operating layer between the signal and the decision.

Interface layer
Ask Marlow
Your AI analyst, fully briefed on every signal below
▲
Advisory layer
GTM Diagnostic
Structured GTM assessment
Market position · ICP coverage · Recommendations
▲
▲
Foundation · always running
Intelligence Brief
Signal ingestion · synthesis · delivery · Tue + Fri
105+
competitors
970+
accounts
16000+
trials
LIVE
01

Intelligence Brief

FREE

Twice-weekly signal synthesis — filtered to what a commercial leader actually needs to act on.

  • →Tuesday and Friday briefs delivered by email — curated from earnings calls, trial registrations, and macro demand signals
  • →Each item: Signal → So What → The Play — with source attribution
  • →Full coverage across all 105+ monitored competitors and 970+ accounts
Inbox
2 new
marlow@marlowiq.com
🔴 Lonza ADC expansion — capacity signal
Today 07:02 · Tue
marlow@marlowiq.com
⚠ Sartorius FY2025 recovery +4.2%
Today 07:02 · Tue
marlow@marlowiq.com
🌐 Macro: VC trough confirmed → demand lag
Today 07:02 · Tue
marlow@marlowiq.com
Agilent Q2 cautious — China/tariff
Fri 14:01 · Prev
54 briefs delivered · next: Tuesday 7am CT
The brief surfaces a signal — Top Opportunities ranks the account.
02

Top Opportunities

INSIGHTS

Signal-triggered GTM plays ranked by urgency — so you always know what to act on this week, this quarter, and what to watch.

  • →Plays organized by urgency bucket: Immediate, This Quarter, and Watch — driven by account press releases, pipeline events, and asset signals
  • →Each opportunity surfaces the triggering signal, the account context, and the recommended commercial action
  • →Updated continuously as new signals land — your GTM priority list reflects what happened this week, not last quarter's planning doc
This Week's Plays
Weekly
Eli Lilly
Phase 3 enrollment opened
Monthly
AstraZeneca
dato-DXd ADC expansion
BioNTech
BNT122 Phase 2 readout
Quarterly
Novartis
PLUVICTO capacity signal
The account is ranked. Customers has the full profile — trials, financials, signals.
03

Customers

INSIGHTS

Deep profiles on 974 life sciences accounts — mIQ buying propensity score, clinical trial activity, pipeline signals, and financials in one view.

  • →mIQ Score (0–100) for every account, recalculated weekly from CT.gov trial activity, pipeline stage, and financial posture — know who is ready to buy before your reps do
  • →16000+ active clinical trials tracked across the account set — phase transitions and breakthrough designations surface automatically in the account score
  • →Full account profile: FDA actions, capacity events, leadership changes, and financial indicators updated from public filings
Eli Lilly LLY
GLP-1Biologics
94
TOP-TIER · ↑ +3
mIQ Score
Score breakdown
Financial Capacity22/25
R&D Commitment18/20
Pipeline Urgency21/25
Commercial Readiness17/20
Signal Velocity9/10
34 active trials · last signal: eloralintide Phase 3 recruiting opened
You have the account depth. Ask Marlow answers the follow-up in seconds.
04

Ask Marlow

PRO

Your Life Sciences intelligence analyst — on call, fully briefed, and already up to speed on your entire account and competitor universe.

  • →AI analyst with your full platform context loaded: mIQ scores, mGS scores, trial data, competitor baselines, macro signals — answers are sourced, not hallucinated
  • →Ask anything: which accounts are most likely to expand capacity, where a competitor is gaining share, how to frame your position for the board
  • →Upload your own docs — call notes, positioning decks, field intel — and Marlow synthesizes internal and external context in the same answer
m
Ask Marlow
● Live context: 974 accounts · 108 competitors · 16000+ trials
Which accounts just hit a Phase 3 milestone this week?
Three this week:
Eli LillymIQ 94
Eloralintide Phase 3 — obesity
AstraZenecamIQ 89
dato-DXd NSCLC Phase 3
BioNTechmIQ 82
BNT122 pancreatic adjuvant
Sources: CT.gov · May 9, 2026
Ask anything about your market...
↑

Also included

Every Insights and Pro subscription includes these alongside the core loop.

Competitor Intelligence

INSIGHTS

Strategic baselines, mGS growth scores, peer financial benchmarks, and guidance history for all 105+ monitored competitors — updated every quarter.

GTM Diagnostic

PRO

AI-powered diagnosis of any company’s market position, ICP coverage, and GTM effectiveness — with four prioritized recommendation categories.

Live and updating
105+
competitors monitored
970+
accounts scored
16000+
active clinical trials tracked

Updated continuously. Synthesized weekly. Available now.